ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0460

Cartilage Damage or (sub)luxation of Finger Joints: Impact on Physical Function in Patients with Rheumatoid Arthritis
Abstract Number: 0461

Complete Description of the Three Pathways of the Complement System in a Series of 430 Patients with Rheumatoid Arthritis
Abstract Number: 0462

Circulating Mediators of Endothelial Dysfunction as Predictors of Incident Heart Failure in Rheumatoid Arthritis
Abstract Number: 0463

Evaluation of Inflammatory Indices as Predictive Biomarkers of Carotid Plaque in Patients with Rheumatoid Arthritis
Abstract Number: 0464

Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population
Abstract Number: 0465

Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays
Abstract Number: 0466

Inpatient Outcomes of Rheumatoid Arthritis in Hospitalized Patients Using Cannabis: Data from the National Inpatient Sample
Abstract Number: 0467

Lung Involvement in Early Rheumatoid Arthritis, Analysis of ERA UCLouvain Brussels FINDRA Cohort
Abstract Number: 0468

Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks
Abstract Number: 0469

SCORE2 Is Superior to SCORE in Predicting the Presence of Carotid Plaques and Intima-media Thickness in Rheumatoid Arthritis Patients: A Cross-sectional Study with Carotid Ultrasound
Abstract Number: 0470

New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers
Abstract Number: 0471

Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis
Abstract Number: 0472

Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis
Abstract Number: 0473

Immune Checkpoint–Induced Arthritis: A Comprehensive Single Cohort Descriptive Analysis from Clinical Evaluation to Histology
Abstract Number: 0474

Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].